Open AccessAntihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial
Author(s) -
Julius Stevo,
Cohn Jay N.,
Neutel Joel,
Weber Michael,
Turlapaty Prasad,
Shen Yannan,
Dong Victor,
Batchelor Alicia,
Lagast Hjalmar
Publication year - 2004
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2004.02440.x
Subject(s) - perindopril , medicine , blood pressure , diastole , clinical trial , sitting , randomized controlled trial , cardiology , pathology
The authors evaluated, in a community‐based open‐label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians' perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and ≤65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high‐risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.